Browse News
Filter News
Found 59 articles
-
Elysium Therapeutics Announces Compelling Human Proof-of-Concept Data for its SMART™ Opioid, O2P™ Hydrocodone Prodrug for Acute Pain that Could Disrupt the Industry by Establishing New Standards for Opioid Safety
3/5/2024
Elysium Therapeutics today announced positive results from a Phase 1, human-proof-of-concept study (O2P-001) investigating the company's proprietary Oral Overdose Protected (O2P™) hydrocodone prodrug for the treatment of moderate-to-severe acute pain.
-
Elysium Health™ Announces Positive Results on Its Product Basis™ Published in Hepatology
10/12/2022
Elysium Health, Inc.™, a leading life sciences company focused on aging research, today announced that the detailed results from its clinical trial on Basis™ (NRPT) in people with non-alcoholic fatty liver disease (NAFLD) were published in Hepatology.
-
Opioid Overdose Market Demand 2022-2030: Increased Use of Synthetic Opioids, Such as Fentanyl, a Powerful Synthetic Opioid is Factor to Driver Growth of Industry
7/27/2022
Forecast to 2030,’ thoroughly examines the Opioid Overdose industry to provide essential data & information for the targeted readers.
-
Elysium Health™ Announces Research at Mayo Clinic to Study Associations Between NAD+ Levels and Senescent Cell Burden and Develop Epigenetic Measures of Cellular Senescence
6/1/2022
Elysium Health, Inc.™, a leading life sciences company focused on aging research, today announced the initiation of research at Mayo Clinic to study associations between circulating nicotinamide adenine dinucleotide (NAD+) levels in healthy adults and senescent cell burden, and to develop novel epigenetic measures of cellular senescence.
-
Brain Health Supplements Market Size 2022-2028- Increasing Geriatric Population And Rising Awareness About Mental Health
5/17/2022
Brain health supplements are made from natural substances or extracts from herbs or plants that essentially boost memory function, attention, focus, and alertness in healthy adults. They have also been proven to be highly effective in the management of sleep, depression, and anxiety.
-
Elysium Health™ Announces New Research Initiative in Partnership With the University of Oxford in Connection With the Landmark INTERBIO-21st Study
4/6/2022
Elysium Health, Inc. has entered into a material transfer agreement with the University of Oxford to analyze the DNA methylation patterns of 2,500 umbilical cord blood samples from the landmark INTERBIO-21st Study.
-
Elysium Health™ Announces Research Partnership with the University of Oxford for the Purpose of Developing Epigenetic Measures of Brain Aging and Health
3/23/2022
Elysium Health, Inc.™, a leading life sciences company focused on aging research, has entered into a material transfer agreement with the University of Oxford to examine hundreds of samples from the VITACOG study to develop epigenetic measures of brain aging and health.
-
Increasing Awareness Regarding Mental Health Issues and Growing Need to Improve Cognitive Performance to Drive Sales of Brain Health Supplements: Reports and Data
12/7/2021
The escalating geriatric populace, surging conciouness about mental health issues, and growing desire to enhance brain functions are the key factors stimulating the market growth.
-
ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge’s Ruling in Patent Infringement Lawsuit
9/15/2021
ChromaDex Corp. (NASDAQ:CDXC) issued the following statement: ChromaDex announced today plans to appeal a September 14 decision granting a Motion for Summary Judgment (MSJ) in its lawsuit for patent infringement against Elysium Health, Inc. (“Elysium”) in the United States District Court for the District of Delaware. ChromaDex licenses U.S. Patent No. 8,383,086
-
BioSpace Movers & Shakers, Aug. 6
8/6/2021
Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers. -
Q32 Bio Announces Appointment of Kathy LaPorte to its Board of Directors
8/3/2021
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced the appointment of Kathy LaPorte to its Board of Directors.
-
ChromaDex Corporation Reports First Quarter 2021 Financial Results
5/6/2021
Tru Niagen® Revenue for the Three-Month Period Ended March 31, 2021 Totals $12.4 Million, up 12% Year-over-Year, with Total Company Revenue of $14.7 Million and Gross Margin of 62.9%.
-
ChromaDex Corporation Reports 2020 Financial Results
3/10/2021
Revenue for the Three-Month Period Ended December 31, 2020 Totals $15.4 Million, up 18% Year-over-Year, with Gross Margin of 61.0%, and Lower Operating Expenses.
-
Thorne Research, Inc., Continues to Challenge the Validity of U.S. Patents on Nicotinamide Riboside
2/4/2021
Thorne Research, Inc., yesterday filed a petition for inter partes review at the U.S. Patent Trial and Appeal Board to challenge Claims 1-3 of U.S. Patent No. 8,197,807, which relates to compositions of nicotinamide riboside for oral administration.
-
Bolt Biotherapeutics Expands Board of Directors with Appointment of Kathleen LaPorte
1/5/2021
Bolt Biotherapeutics Inc., a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems, today announced the appointment of Kathleen LaPorte, to its Board of Directors
-
Clinical Catch-Up: December 14-18
12/21/2020
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look. -
Elysium Health™ Announces Initiation of Phase II Clinical Trial at Mayo Clinic to Evaluate BASIS™ for Prevention of Acute Kidney Injury After Cardiac Surgery
12/15/2020
Elysium Health, Inc.,TM a life sciences company developing clinically validated health products based on aging research, announced the initiation of a Phase II clinical trial at Mayo Clinic to evaluate the efficacy of BASISTM for the prevention of acute kidney injury in patients that have undergone a cardiac surgery.
-
Thorne Research, Inc. Challenges the Validity of U.S. Patent of Pharmaceutical Compositions of Nicotinamide Riboside
12/2/2020
Thorne Research, Inc., yesterday filed a petition for inter partes review at the U.S. Patent Trial and Appeal Board to challenge Claim 2 of U.S. Patent No. 8,383,086, which relates to pharmaceutical compositions of nicotinamide riboside.
-
ChromaDex Corporation Reports Third Quarter 2020 Financial Results
11/4/2020
ChromaDex Corp. (Nasdaq:CDXC) today reported third quarter financial results.
-
ChromaDex Corporation Reports Second Quarter 2020 Financial Results
8/6/2020
“We achieved record net sales of $15.3 million in the second quarter while maintaining our focus on the science, announcing our 200th research agreement and tenth published human trial on Niagen®,” says ChromaDex CEO Rob Fried.